Featured Research

from universities, journals, and other organizations

New Drug Shown Effective Against Vancomycin-Resistant Bacteria

Date:
March 10, 1999
Source:
Northwestern University
Summary:
Northwestern University Medical School researchers have successfully used a new investigational drug, linezolid, in a patient with a severe bacterial infection that was resistant to all antibiotics, including vancomycin.

CHICAGO --- Northwestern University Medical School researchers have successfully used a new investigational drug, linezolid, in a patient with a severe bacterial infection that was resistant to all antibiotics, including vancomycin.

Linezolid is a member of a new class of antibacterial drugs called oxazolidinones that are chemically unrelated to currently used antibiotics yet have enhanced activity against gram-positive bacteria, including enterococci that are resistant to vancomycin, a potent antibiotic.

Because the bacteria Enterococcus faecium is highly resistant to vancomycin as well as other antibiotics, there are few, if any, therapeutic options for patients who develop these infections. The outcome in patients infected with this bacteria is generally poor due to a lack of effective antibiotics, said Gary A. Noskin, M.D., an infectious disease specialist who headed the study at Northwestern.

Noskin, an associate professor of medicine, and his colleagues at the Medical School described their experience with linezolid in an article in the March issue of the journal Clinical Infectious Disease.

Following chemotherapy for lymphoma, the patient had a decreased level of neutrophils, cells that play an important role in fighting infection. She subsequently developed a vancomycin-resistant enterococcal (VRE) bloodstream infection that was resistant to all antimicrobial therapies, including vancomycin. She was then given linezolid, which was administered under a "compassionate use" exemption, in combination with gentamicin, another antibiotic.

Blood cultures taken on four consecutive days prior to the initiation of linezolid therapy were positive for VRE, as was a single culture after treatment was initiated. All subsequent blood cultures and specimens were negative for VRE while she received linezolid treatment and at 14 and 30 days following completion of therapy.

Noskin said that in the absence of this medicine, the patient would have died from her infection. He added that the clinical response is rewarding and confirms work he has done in the laboratory verifying the activity of this antibiotic.

However, he cautioned that further studies involving larger numbers of patients are necessary to determine the efficacy of linezolid for patients with serious enterococcal infections.

"Until effective therapy is demonstrated, the emphasis must remain on prevention of VRE. This includes the judicious use of antimicrobial drugs and strict adherence to established infection control procedures," Noskin said.

Noskin?s co-researchers on this study were Lance R. Peterson, M.D., professor of pathology; Farida Siddiqui; Valentina Stosor, M.D., clinical instructor in medicine; and Julie Kruzynski.

The linezolid administered to this patient was supplied through a compassionate use program by Pharmacia and Upjohn, Kalamazoo, Mich.


Story Source:

The above story is based on materials provided by Northwestern University. Note: Materials may be edited for content and length.


Cite This Page:

Northwestern University. "New Drug Shown Effective Against Vancomycin-Resistant Bacteria." ScienceDaily. ScienceDaily, 10 March 1999. <www.sciencedaily.com/releases/1999/03/990310053904.htm>.
Northwestern University. (1999, March 10). New Drug Shown Effective Against Vancomycin-Resistant Bacteria. ScienceDaily. Retrieved September 22, 2014 from www.sciencedaily.com/releases/1999/03/990310053904.htm
Northwestern University. "New Drug Shown Effective Against Vancomycin-Resistant Bacteria." ScienceDaily. www.sciencedaily.com/releases/1999/03/990310053904.htm (accessed September 22, 2014).

Share This



More Health & Medicine News

Monday, September 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com
Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins